Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

ALNY· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +69.0% in FY2025

Yvonne L. Greenstreet, M.D. is the CEO of Alnylam Pharmaceuticals and was paid $14.9M in FY2025 (Dec), up 29%.

Pay$100 in the stock at the end of FY21 → $234
CEO pay is from each Alnylam Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Yvonne L. Greenstreet, M.D.FY2025
  2. 2Jeffrey V. PoultonFY2025
  3. 3Bryan A. SupranFY2025
  4. 4Pushkal Garg, M.D.FY2025
  5. 5Tolga TangulerFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Alnylam Pharmaceuticals paid its 5 named executives $41.2M in total in FY2025 (Dec). CEO Yvonne L. Greenstreet, M.D. was paid $14.9M of that.

Name
Yvonne L. Greenstreet, M.D.Chief Executive Officer (principal executive officer)
Jeffrey V. PoultonExecutive Vice President, Chief Financial Officer (principal financial officer)
Bryan A. SupranExecutive Vice President, Chief Legal Officer and SecretaryNot disclosedNot disclosed
Pushkal Garg, M.D.Executive Vice President, Chief Research and Development Officer
Tolga TangulerExecutive Vice President, Chief Commercial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers12

See all

The FY2025 (Dec) proxy of Alnylam Pharmaceuticals names 12 peer companies for pay. Among Alnylam Pharmaceuticals and these peers, CEO pay was 4th highest of 5 and total shareholder return was the highest of 5.

4th highest of 5in Alnylam Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$7.3M$32.1M

1st highest of 5in Alnylam Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$28$306

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Phillip A. SharpDirector · 21 yr on the boardIndependentScience and Technology (Chair)—Paid as an executive
  • Michael W. BonneyDirector · 9 yr on the boardNot independent—Paid as an executive

The board of the latest proxy (FY2023).

Activity

  1. Pay
    Alnylam Pharmaceuticals CEO pay rose 29% to $14.9M. The stock rose 69% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Alnylam Pharmaceuticals Division head pay rose 123% to $6.1M. The stock rose 69% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Alnylam Pharmaceuticals Division head pay rose 122% to $6.5M. The stock rose 69% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Alnylam Pharmaceuticals CFO pay rose 81% to $6.9M. The stock rose 69% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Alnylam Pharmaceuticals CEO pay rose 29% to $11.5M. The stock rose 23% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Alnylam Pharmaceuticals CEO pay rose 94% to $8.9M. The stock fell 19% in FY2023 (Dec).
    DEF 14A
  7. Pay
    Alnylam Pharmaceuticals Division head pay fell 66% to $2.4M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Alnylam Pharmaceuticals Division head pay fell 28% to $2.9M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Alnylam Pharmaceuticals Executive Vice President, Chief Scientific Officer pay rose 14% to $2.8M. The stock fell 19% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Alnylam Pharmaceuticals CFO pay rose 18% to $3.8M. The stock rose 23% in FY2024 (Dec).
    DEF 14A
  11. Pay
    Alnylam Pharmaceuticals CFO pay fell 13% to $2.4M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  12. Pay
    Alnylam Pharmaceuticals Division head pay rose 22% to $2.9M. The stock fell 19% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Alnylam Pharmaceuticals Division head pay rose 11% to $3.2M. The stock fell 19% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Alnylam Pharmaceuticals CEO pay rose 94% to $8.9M. The stock fell 19% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Alnylam Pharmaceuticals CEO pay fell 46% to $4.6M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  16. Pay
    Alnylam Pharmaceuticals CFO pay rose 33% to $3.2M. The stock fell 19% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Alnylam Pharmaceuticals General counsel pay fell 64% to $2.0M. The stock fell 19% in FY2023 (Dec).
    DEF 14A
  18. Pay
    Alnylam Pharmaceuticals Former President pay fell 34% to $3.6M. The stock rose 40% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 6, 2026FY2025
Annual report10-KFeb 12, 2026FY2025
Proxy statementDEF 14AMar 24, 2025FY2024
Annual report10-KFeb 13, 2025FY2024
Proxy statementDEF 14AApr 1, 2024FY2023
Annual report10-KFeb 15, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data